Clinical trialObservationalRecruiting
Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma
The Emerging Issue - Pancreatic Steatosis Prevalence in Pancreatic Cystic Neoplasms and Adenocarcinoma: Insights From a Single-center Retrospective Study
- Outcome
- Ongoing
- Phase
- Observational
- Status
- Recruiting
- Study type
- Observational
- Start
- 1 January 2019
- Listed end
- 30 June 2025
- Enrollment
- 66 participants
- Sites
- 1
- Primary outcomes
- increased prevalence of pancreatic steatosis in neoplastic cystic lesions
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 10 March 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS). The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.
Detailed description public domain (ClinicalTrials.gov)
Pancreatic steatosis has gained significant novel interest in the pathophysiology of PDAC and neoplastic cystic lesions. Pancreatic steatosis is the new emerging issue in pancreatology. Recently, pancreatic steatosis has gained significant novel interest in the pathophysiology of PDAC. The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. Pancreatic ductal adenocarcinoma (PDAC) has a poor survival, predominantly as a result of its diagnosis in advanced stages. Pathological changes of steatosis are an independent determinant of PDAC, and these pathological changes are correlated with the attenuation of the pancreas on computed tomography (CT). The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.
Papers 3
- Builds on itEmerging Issue - Fatty Pancreas in Pancreatic Cystic Neoplasms: Results of a Matched Case-Control Study. DOI 10.1007/s10620-026-10174-7↗
- BackgroundPancreatic Fat Content Detected by Computed Tomography and Its Significant Relationship With Intraductal Papillary Muci… DOI 10.1097/mpa.0000000000001103↗
- BackgroundObesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN). DOI 10.1158/1078-0432.ccr-14-2385↗